The present application relates to methods of using humanized antibodies that specifically bind to hepcidin to quantify hepcidin in a fluid sample. Another aspect relates to discriminating, using quantified plasma hepcidin levels, between a subject with a condition due to biallelic TMPRSS6 mutation and other chronic iron deficiency/iron deficiency anemia. Another aspect relates to methods of treatment of a disease or condition related to hepcidin comprising use of humanized antibodies which bind hepcidin to determine hepcidin levels in the subject.
展开▼
